<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157884">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01667393</url>
  </required_header>
  <id_info>
    <org_study_id>IDEV  POP-01-US/OUS</org_study_id>
    <nct_id>NCT01667393</nct_id>
  </id_info>
  <brief_title>Popliteal Artery of Treatment With Balloon Angioplasty vs. SUPERA VERITAS Peripheral Stent System</brief_title>
  <acronym>PARADIGM</acronym>
  <official_title>Popliteal Artery Trial of Patients Undergoing Treatment With Balloon Angioplasty vs. the Adaptive SUPERA VERITAS Peripheral Stent System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IDev Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IDev Technologies, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unblinded, randomized, balanced trial comparing 12 month target lesion patency rates of the
      IDEV SUPERA VERITAS peripheral stent system to PTA in the treatment of obstructive
      atherosclerotic popliteal artery disease.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary patency</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary efficacy will be target lesion primary patency at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MAE-free survival rate.</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Major Adverse Event-free survival rate that is non-inferior to that of PTA at 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">318</enrollment>
  <condition>Peripheral Vascular Disease.</condition>
  <arm_group>
    <arm_group_label>IDEV SUPERA Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following PTA of the target lesion, the SUPERA stent will be delivered to the treated segment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous Transluminal Angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The target lesion will be treated by PTA alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IDEV SUPERA Stent</intervention_name>
    <arm_group_label>IDEV SUPERA Stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous Transluminal Angioplasty</intervention_name>
    <arm_group_label>Percutaneous Transluminal Angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has lifestyle limiting claudication or rest pain or at least a single de novo
             or restenotic popliteal artery lesion.

        Exclusion Criteria:

          -  Inteervention distal to the target lesion is required at the time of the index
             procedure or within 30 days after the index procedure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Carol C Base, BSN, MS</last_name>
    <phone>281-525-2000</phone>
    <email>cbase@idevmd.com</email>
  </overall_contact>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 15, 2012</lastchanged_date>
  <firstreceived_date>August 14, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
